# Amy Salzhauer

> Amy Salzhauer is a Series A investor at Good Growth Capital backing Biotechnology and Health Care. See 10 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Good Growth Capital](https://shizune.co/investors/profile/good-growth-capital)
- Location: Charleston, United States
- Total investments: 10
- Last investment: Nov 2024
- Lead investor: 50%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/amy-salzhauer-385126/

Amy Salzhauer is a Founder and Managing Partner at Good Growth Capital, a majority women-owned venture capital fund that is known for its world-leading expertise in technology commercialization, and for finding, funding and growing superior, defensible technology companies that fill pressing societal needs. She was previously the CEO of IgnitionVentures, where she helped start companies worth over US $1 billion out of science labs in areas such as chip-based fuel cells, self-organizing networks, selective brain cooling, and advanced materials.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 30% |
| Health Care | 2 | 20% |
| Medical Device | 2 | 20% |
| Medical | 1 | 10% |
| Therapeutics | 1 | 10% |

7 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 3 | 30% |
| Seed | 1 | 10% |
| Funding Round | 1 | 10% |
| Convertible Note | 1 | 10% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 3 | 30% |
| France | 1 | 10% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| AdipoPharma | AdipoPharma SAS is dedicated to learning more about the role of adipocyte cells in diabetes. AdipoPharma is using the adipocyte's power to treat insulin resistance, type 2 diabetes, and other diseases. |  |  | Nov 11, 2024 |  |
| AdipoPharma | AdipoPharma SAS is dedicated to learning more about the role of adipocyte cells in diabetes. AdipoPharma is using the adipocyte's power to treat insulin resistance, type 2 diabetes, and other diseases. | $10.6M | Series A | Nov 11, 2024 |  |
| AdipoPharma | AdipoPharma SAS is dedicated to learning more about the role of adipocyte cells in diabetes. AdipoPharma is using the adipocyte's power to treat insulin resistance, type 2 diabetes, and other diseases. |  | Series A | Jan 23, 2023 |  |
| Leuko | Leuko Labs develops non-invasive white blood cell monitoring device. White blood cell assessment is a first-line indicator for various medically-relevant situations, ranging from chemotherapy management to the detection of life threatening infections worldwide. This test is currently invasive and not readily accessible - it requires patient travel,blood draws and laboratory infrastructure. Though its white blood cell monitoring device PointCheck, immunosuppressed patients can now be tested more frequently, moving towards improved quality of life and improved clinical outcomes. | $5M | Series A | Sep 23, 2022 |  |
| Obsidio | Obsidio, Inc. is an early-stage medical device company pioneering a biomaterial platform technology to enable minimally-invasive occlusion of blood vessels anywhere in the body regardless of the patient’s coagulopathy. The technology can be used to control bleeding, close off vessels supplying blood to tumor, eliminate abnormal connections betweenarteries and veins, and treat aneurysms. | $1.1M | Convertible Note | Jul 30, 2020 |  |
| Obsidio | Obsidio, Inc. is an early-stage medical device company pioneering a biomaterial platform technology to enable minimally-invasive occlusion of blood vessels anywhere in the body regardless of the patient’s coagulopathy. The technology can be used to control bleeding, close off vessels supplying blood to tumor, eliminate abnormal connections betweenarteries and veins, and treat aneurysms. | $116.7K | Convertible Note | May 06, 2020 |  |
| Obsidio | Obsidio, Inc. is an early-stage medical device company pioneering a biomaterial platform technology to enable minimally-invasive occlusion of blood vessels anywhere in the body regardless of the patient’s coagulopathy. The technology can be used to control bleeding, close off vessels supplying blood to tumor, eliminate abnormal connections betweenarteries and veins, and treat aneurysms. | $300K | Convertible Note | May 31, 2019 |  |
| Obsidio | Obsidio, Inc. is an early-stage medical device company pioneering a biomaterial platform technology to enable minimally-invasive occlusion of blood vessels anywhere in the body regardless of the patient’s coagulopathy. The technology can be used to control bleeding, close off vessels supplying blood to tumor, eliminate abnormal connections betweenarteries and veins, and treat aneurysms. | $50K | Convertible Note |  |  |
| Skyhawk Therapeutics | Skyhawk Therapeutics is a provvider of small molecule therapeutics designed to offer therapies that correct RNA expression.The company's therapeutics use proprietary technology that helps the rational design of small molecules that target specific binding pocket regions on RNA, using both sequence and structural specificity, at particularmoments in the RNA splicing process, enabling physicians to target diseases driven by a type of RNA mis-splicing called exon skipping. |  | Series A |  |  |
| Obsidio | Obsidio, Inc. is an early-stage medical device company pioneering a biomaterial platform technology to enable minimally-invasive occlusion of blood vessels anywhere in the body regardless of the patient’s coagulopathy. The technology can be used to control bleeding, close off vessels supplying blood to tumor, eliminate abnormal connections betweenarteries and veins, and treat aneurysms. |  | Seed |  |  |

10 of 10 investments shown.

## Co-investors
- [Newton Biocapital](https://shizune.co/investors/profile/newton-biocapital) — VC Fund, 3 deals together
- [InvestSud](https://shizune.co/investors/profile/investsud-9c11) — VC Fund, 2 deals together
- [Okeanos](https://shizune.co/investors/profile/riverbend-capital) — VC Fund, 2 deals together
- [Sambrinvest](https://shizune.co/investors/profile/sambr-invest) — VC Fund, 2 deals together
- [HTH](https://shizune.co/investors/profile/hth) — VC Fund, 1 deal together
- [IAG Capital Partners](https://shizune.co/investors/profile/iag-capital-partners) — VC Fund, 1 deal together

## About Good Growth Capital

VC Fund · Charleston, United States

Good Growth Capital provides investors with exceptional returns through our ability to source, assess and invest in early-stage transformative science- and technology-based companies in life sciences, data sciences, and greentech/hard sciences.

5 contacts available at Good Growth Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Amy Salzhauer | Founder and Managing Partner | https://shizune.co/investors/profile/amy-salzhauer |
| Carolyne LaSala | Partner and Managing Partner | https://shizune.co/investors/profile/carolyne-lasala |
| DAVID MENDEZ | Managing Partner | https://shizune.co/investors/profile/david-mendez-2 |
| DAVID MENDEZ | Managing Partner | https://shizune.co/investors/profile/david-mendez |
| John Osborne | Managing Partner | https://shizune.co/investors/profile/john-osborne-3 |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Amy Salzhauer invest in?

Amy Salzhauer invests primarily in Biotechnology, Health Care and Medical Device startups, most often at Series A and Seed stage. Most of the 10 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Amy Salzhauer last invest?

The most recent investment recorded for Amy Salzhauer closed in Nov 2024. Shizune tracks 10 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co